Header

Lymphoma Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 31 in total

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma subjects.

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 14-242

Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL

This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after aut...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 14-566

Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

This Phase II studyis designed to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in 18 subjects with advanced Peripheral T-Cell Lymphoma (PTCL). The tota...

Diagnosis: Lymphoma

Phase: 2

Protocol Number:

AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma

This phase II trial studies how well AT13387 works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previou...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 16-712

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy. This drug blocks...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 16-104

Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy

The purpose of this study is to determine the side effects of treatment with Nivolumab alone and in combination with Ipilimumab in subjects with hematological malignancies and the dose that should ...

Diagnosis: Hodgkin's Lymphoma, Lymphoma

Phase: 1

Protocol Number: 12-317

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

The purpose of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematolo...

Diagnosis: Lymphoma

Phase: 1

Protocol Number:

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

This research study will be evaluating the safety and efficacy of a study drug called TGR-1202 in combination with a known drug ibrutinib, also known as Imbruvica, as a possible treatment for Chron...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 14-396

A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies

This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in p...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-212

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-105

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Diagnosis: Lymphoma, Solid Tumor/Phase I

Phase: 1

Protocol Number:

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

This is a Phase 1 dose exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK) and preliminary activity w...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-421

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)

This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and ...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-404

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered d...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-229

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

The purpose of this study is to test the safety of a study drug called duvelisib.

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 16-570

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are cu...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-044

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Dir...

Diagnosis: Solid Tumor/Phase I, Multiple Myeloma, Lymphoma

Phase:

Protocol Number: 16-406

Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection.

Diagnosis: Solid Tumor/Phase I, Lymphoma

Phase:

Protocol Number: 16-274

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refra...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-272

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Test...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-340

Study of Allogeneic EBV-CTLs in EBV-Associated Viremia or Malignancies

This is a multicenter expanded access protocol to provide human leukocyte antigen (HLA) partially-matched third-party allogeneic EBV-CTLs for the treatment of EBV-associated viremia and disease for...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-535

A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a phase 1-2, open-label study in subjects with refractory DLBCL, evaluating the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in co...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-436

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome

This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, EPOCH-R, as a possible treatment for Richter's Syndrome. The drugs involved i...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-596

Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers

Phase 1b (Dose Escalation) in primarily CLL/SLL patients will evaluate safety and pharmacology of self-administered twice a day oral doses beginning at 25 mg/dose for 4 weeks with succeeding cohort...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-139

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-063

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-078

Cyclophosphamide and Alemtuzumab In Lymphoma

This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study intervention...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-034

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is sa...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-615

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma. The Phase 2 portion of the study will investigat...

Diagnosis: Lymphoma, Multiple Myeloma

Phase:

Protocol Number: 17-262

Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies

This clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma

Diagnosis: Solid Tumor/Phase I, Lymphoma

Phase:

Protocol Number: 17-334

1
<< Previous
'